NCT03688152 is a Phase 1 clinical trial of INCB053914 in Relapsed Diffuse Large B-Cell Lymphoma, sponsored by Incyte Corporation.

Who is sponsoring NCT03688152?

NCT03688152 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03688152?

Interventions in NCT03688152: INCB053914, INCB050465.

What condition does NCT03688152 study?

NCT03688152 studies Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma.

Is NCT03688152 still recruiting?

NCT03688152 is currently completed. Last updated 10 November 2020.

Last reviewed 2020-11-10 · How we verify

NCT03688152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Completed Phase 1 Last updated 10 November 2020

What this trial tests

Phase 1 trial testing INCB053914 in Relapsed Diffuse Large B-Cell Lymphoma in 9 participants. Completed in 1 September 2020.

Timeline

3 December 2018

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	3 December 2018
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	3 locations across United States

Drugs / interventions tested

INCB053914 — full drug profile →
INCB050465 — full drug profile →

Conditions studied

Relapsed Diffuse Large B-Cell Lymphoma — all drugs for Relapsed Diffuse Large B-Cell Lymphoma →
Refractory Diffuse Large B-Cell Lymphoma — all drugs for Refractory Diffuse Large B-Cell Lymphoma →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Relapsed Diffuse Large B-Cell Lymphoma or Refractory Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
Jiang N, Dai Q, Su X, Fu J, et al · · 2020 · cited 419× · PMID 32333246 · DOI 10.1007/s11033-020-05435-1
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.
Darici S, Alkhaldi H, Horne G, Jørgensen HG, et al · · 2020 · cited 87× · PMID 32932888 · DOI 10.3390/jcm9092934
Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M, Nicot C. · · 2023 · cited 58× · PMID 36694243 · DOI 10.1186/s12943-023-01721-1
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.
Profitós-Pelejà N, Santos JC, Marín-Niebla A, Roué G, et al · · 2022 · cited 33× · PMID 35205606 · DOI 10.3390/cancers14040860
Targeting PIM Kinases to Improve the Efficacy of Immunotherapy.
Clements AN, Warfel NA. · · 2022 · cited 12× · PMID 36429128 · DOI 10.3390/cells11223700
Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy.
Cui R, Luo Z, Zhang X, Yu X, et al · · 2025 · cited 10× · PMID 40266213 · DOI 10.3390/vaccines13030292
The Role of PIM Kinases in Pediatric Solid Tumors.
Julson JR, Marayati R, Beierle EA, Stafman LL. · · 2022 · cited 5× · PMID 35892829 · DOI 10.3390/cancers14153565

Verify or expand the search:

Other trials of INCB053914

Trials testing the same drug.

NCT02587598 — Study of INCB053914 in Subjects With Advanced Malignancies · Phase 1, PHASE2 · terminated

Other recruiting trials for Relapsed Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT04572763 — Copanlisib Plus Venetoclax in R/R DLBCL · Phase 1, PHASE2 · active not recruiting
NCT04384484 — Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refra · Phase 3 · active not recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03688152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 10 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03688152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing